New drug ISM8969 enters first human safety tests
NCT ID NCT07581431
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 1 trial is testing the safety and tolerability of a new drug called ISM8969 in healthy adults and obese adults at risk of heart disease. About 100 participants will receive either the drug or a placebo. The study aims to see how the body processes the drug and if it causes any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ISM8969
- What this could lead to
- If successful, this early study could pave the way for future trials of ISM8969 as a potential treatment for conditions related to obesity and cardiovascular risk.
- What could go wrong
- This is a very early Phase 1 trial focused on safety, not effectiveness. The drug may prove unsafe or ineffective in later studies. Side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ELDERLY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nucleus Network Pty Ltd.
RECRUITINGMelbourne, Victoria, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A two-session balance workout may cut fall risk in seniors
- Salty air: a new way to help lungs sweep themselves clean?
- First human test of SSGJ-626: will it be safe?
- Scientists to test how healthy bodies react to exercise in thin air
- Does stretching after weights change how your heart recovers?
- Could heart disease start outside the heart? new imaging study aims to find out